Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.
EP. 1: Treatment Considerations for Triple-Class Refractory MM
Sagar Lonial, MD, FACP, discusses factors to consider when selecting later lines of therapy for patients with triple-class refractory multiple myeloma (MM).
EP. 2: BCMA-Targeting Agents for Heavily Pretreated MM
An expert in multiple myeloma considers rationale for targeting BCMA and discusses recent FDA approval of belantamab mafodotin based on the DREAMM 2 trial.
EP. 3: Managing Toxicities of Belantamab Mafodotin
A key opinion leader in medical oncology reviews optical and hematological toxicities of belantamab mafodotin and discusses how to mitigate adverse events.
EP. 4: Monitoring Ocular Events With Eye Care Specialists
Sagar Lonial, MD, FACP, emphasizes the importance of partnering with eye care specialists to manage optical toxicities of patients taking belantamab mafodotin.
EP. 5: Future Developments of Belantamab Mafodotin
A leading authority in multiple myeloma comments on the future of belantamab mafodotin, such as combination therapy based on the DREAMM 5 and DREAMM 8 trials.
2 Clarke Drive Cranbury, NJ 08512